Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a <scp>SEER</scp>‐medicare analysisSikander Ailawadhi, Asher Chanan‐Khan, Ryan D. Frank et al.|Cancer Medicine|2017Cited by 88
Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparitiesSikander Ailawadhi, Asher Chanan‐Khan, Ryan D. Frank et al.|Cancer|2018Cited by 55
Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label TrialSikander Ailawadhi, Yifan Zhai, Zi Chen et al.|Clinical Cancer Research|2023Cited by 38
<scp>AT</scp>‐101 downregulates <scp>BCL</scp>2 and <scp>MCL</scp>1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and <scp>W</scp>aldenström macroglobulinaemiaAneel Paulus, Asher Chanan‐Khan|British Journal of Haematology|2013Cited by 36
Landmark Cancer Clinical Trials and Real-World Patient Populations: Examining Race and Age ReportingThejus Jayakrishnan, Sikander Ailawadhi, Aneel Paulus et al.|Cancers|2021Cited by 20